ABSTRACT
Objetivo: refletir sobre a importância do trabalho das equipes de reabilitação, orientando e habilitando os cadeirantes para o desempenho seguro das transferências diárias, fundamentais na realização das atividades cotidianas e inclusão social. Métodos: trata-se de estudo teórico-reflexivo fundamentado na teoria do déficit de autocuidado, com a utilização integrada dos diagnósticos de enfermagem, da classificação internacional das práticas de enfermagem e do instrumento de avaliação das transferências, adequados às necessidades de pessoas com lesão medular, atendidas nos ambientes institucionais de cuidados, visando o preparo para o desempenho das atividades cotidianas. Resultados: cabe aos enfermeiros assumir liderança nas equipes de reabilitação física, norteando suas intervenções no treinamento dessas pessoas e seus cuidadores para o desempenho e ajuda segura nas transferências para cuidar de si. Conclusão: considerando a lesão medular entre os maiores problemas da saúde coletiva que afeta a humanidade contemporânea, tanto pelos comprometimentos na qualidade de vida das pessoas, quanto no aumento das despesas hospitalares e reabilitação requeridos, a adoção de estratégias de cuidados preventivos de complicações musculoesqueléticas é sempre bem-vinda. Essas pessoas, quando não orientadas, executam movimentos repetitivos para se deslocar em transferências de uma superfície para outra, correndo elevados riscos de contrair lesões nas articulações, pele e mucosas. (AU)
Objective: to reflect on the importance of the work of rehabilitation teams, guiding and enabling wheelchair users to safely perform daily transfers, essential for carrying out daily activities and social inclusion. Methods: this is a theoretical-reflective study based on the theory of self-care deficit, with the integrated use of nursing diagnoses, the international classification of nursing practices and the transfer assessment instrument, adapted to the needs of people with spinal cord injury, attended in institutional care environments, aiming to prepare for the performance of daily activities. Results: it is up to nurses to assume leadership in physical rehabilitation teams, guiding their interventions in the training of these people and their caregivers for performance and safe help in transfers to take care of themselves. Conclusion: considering spinal cord injury among the biggest collective health problems that affect contemporary humanity, both because of the compromises in people's quality of life, as well as the increase in hospital and rehabilitation expenses required, the adoption of preventive care strategies for musculoskeletal complications is always welcome. These people, when not guided, perform repetitive movements to move in transfers from one surface to another, running high risks of contracting injuries to the joints, skin and mucous membranes. (AU)
Objetivo: reflexionar sobre la importancia del trabajo de los equipos de rehabilitación, orientando y capacitando a los usuarios de silla de ruedas para realizar con seguridad las tranferencias cotidianas, indispensables para el desarrollo de las actividades cotidianas y la inclusión social. Métodos: se trata de un estudio teórico-reflexivo basado en la teoría del déficit de autocuidado, con el uso integrado de los diagnósticos de enfermería, la clasificación internacional de prácticas de enfermería y el instrumento de evaluación de la transferencia, adaptado a las necesidades de las personas con lesión medular. asistidos en ambientes de atención institucional, con el objetivo de preparar para el desempeño de las actividades diárias. Resultados: corresponde a los enfermeros asumir el liderazgo en los equipos de rehabilitación física, orientando sus intervenciones en la formación de esas personas y sus cuidadores para el desempeño y ayuda segura en las transferencias para cuidarse. Conclusion: considerando la lesión medular entre los mayores problemas de salud colectiva que afectan a la humanidad contemporánea, tanto por los compromisos en la calidad de vida de las personas, como por el aumento de los gastos hospitalarios y de rehabilitación requeridos, la adopción de estrategias de atención preventiva de las complicaciones musculoesqueléticas siempre es bienvenido Estas personas, cuando no están guiadas, realizan movimientos repetitivos para moverse en transferencias de una superficie a otra, corriendo un alto riesgo de contraer lesiones en las articulaciones, piel y mucosas. (AU)
Subject(s)
Transfer Factor , Wheelchairs , Rehabilitation Nursing , Standardized Nursing Terminology , Trauma NursingABSTRACT
Allergic rhinitis (AR) has considerable impact on the general health of individuals. Therefore, treatment trials should include an evaluation of quality of life. We aimed to determine changes in the quality of life of moderate/severe AR patients treated with standard treatment in addition to dialyzable leukocyte extract (DLE), a peptide-based immunomodulator. In a prospective, non-controlled trial, DLE was added to the standard treatment regimen for patients with moderate/severe AR. DLE was administered orally at 2 mg per day for 5 days, followed by 4 mg per week for 5 weeks, and then 2 mg per week for 5 weeks. The primary endpoints were overall improved Standardized Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores, domain scores, and individual item scores of 0.5 points or higher. Statistical significance was defined as P < .05. Thirty patients (50% female) aged 14 to 60 years old (33.4 ± 11.9) were enrolled in this study. The mean overall basal quality of life score was 3.41 ± 1.22. After 11 weeks, the mean RQLQ score was 1.74 ± 1.09 ( P < .0001; 95% confidence interval [CI], 1.05-2.33), and all the domain scores improved (daily activities P < .001, 95% CI 0.91-2.15, sleep P < .001, 95% CI 0.9-2.26, non-hay fever symptoms P = .001, 95% CI 0.51-1.82, practical problems P < .001, 95% CI 1.55-2.85, nasal symptoms P < .001, 95% CI 1.36-2.67, ocular symptoms P < .001, 95% CI 1.05-2.17, emotional P < .001, 95% CI 1.23-2.55). Each of the 28 individual item scores on the RQLQ showed clinical (minimal important difference [MID] ≥ 0.5) and statistical ( P < .05) improvements. DLE might be a beneficial adjuvant treatment for AR. Our results provide preliminary data for future research. Clinical trials registration ID: NCT02506998.
Subject(s)
Conjunctivitis , Rhinitis, Allergic , Adolescent , Adult , Female , Humans , Male , Middle Aged , Young Adult , Prospective Studies , Quality of Life , Rhinitis, Allergic/drug therapy , Surveys and Questionnaires , Transfer FactorABSTRACT
During the ripening process, the pericarp of chili pepper (Capsicum spp.) fruits accumulates large amounts of carotenoids. Although the carotenoid biosynthesis pathway in the Capsicum genus has been widely studied from different perspectives, the transcriptional regulation of genes encoding carotenoid biosynthetic enzymes has not been elucidated in this fruit. We analyzed RNA-Seq transcriptomic data from the fruits of 12 accessions of Capsicum annuum during the growth, development, and ripening processes using the R package named Salsa. We performed coexpression analyses between the standardized expression of genes encoding carotenoid biosynthetic enzymes (target genes (TGs)) and the genes of all expressed transcription factors (TFs). Additionally, we analyzed the promoter region of each biosynthetic gene to identify putative binding sequences for each selected TF candidate. We selected 83 TFs as putative regulators of the carotenogenic structural genes. From them, putative binding sites in the promoters of the carotenoid-biosynthesis-related structural genes were found for only 54 TFs. These results could guide the search for transcription factors involved in the regulation of the carotenogenic pathway in chili pepper fruits and might facilitate the collection of corresponding experimental evidence to corroborate their participation in the regulation of this biosynthetic pathway in Capsicum spp.
Subject(s)
Capsicum , Capsicum/metabolism , Carotenoids/metabolism , Fruit/metabolism , Gene Expression Regulation, Plant , RNA-Seq , Transcription Factors/genetics , Transcription Factors/metabolism , Transfer Factor/genetics , Transfer Factor/metabolismABSTRACT
The aim of the present study is to assess soil Cd and Pb contamination in kale (Brassica oleracea var. acephala) production sites in mountain agroecosystem, as well as its potential risk to human health. The study was carried out within 24 kale-production sites located in mountainous region of Rio de Janeiro (Brazil). Soil, plant, and fertilizer samples were collected in all assessed properties. Pseudo-total and bioavailable soil Cd and Pb content and their concentration and amount accumulated in plants were analyzed. The recorded results were used to calculate the pollution index. Risks to human health associated with kale consumption were assessed by comparing the limits set by the Brazilian regulating agency and by calculating estimated daily intake (EDI), noncarcinogenic target hazard quotient (THQ), and carcinogenic risk factor (CRF). Soil Cd and Pb enrichment was observed. Inappropriate management adopted in the assessed sites and terrain slope and the intensive use of mineral (phosphate and potassium) and organic (poultry litter) fertilizers were the main factors contributing to increase soil Cd and Pb pseudo-total and bioavailability contents. Most Cd and Pb contents in leaves, in natura, exceed the maximum values set by the Brazilian regulating agency. The present EDI, THQ, and CRF results recorded for these metals were within the tolerable ranges.
Subject(s)
Brassica , Metals, Heavy , Soil Pollutants , Brazil , Cadmium/analysis , Environmental Monitoring , Fertilizers/analysis , Humans , Lead , Metals, Heavy/analysis , Soil , Soil Pollutants/analysis , Transfer FactorABSTRACT
The objectives of this study was to diagnose Cd and Pb contamination in soil and to identify the main factors that contribute to the transfer of these elements to tomato plants and fruits and contamination levels of the fruits in tropical mountain conditions. Contamination of the study area soils by Cd and Pb was verified. This contamination stemmed from the intensive use of agricultural inputs, mainly organic fertilizers and soluble mineral fertilizers. The relief of the terrain and inadequate soil management influenced the spatial distribution of these two metals. The Cd concentration in tomato fruits was very low, but the Pb contamination detected in approximately 80% of the fruit samples was considerably higher than the limits that pose a danger to human health. The translocation of Pb to the tomato fruits was associated with the use of organic fertilizer, mainly poultry litter.
Subject(s)
Cadmium/analysis , Lead/analysis , Soil Pollutants/analysis , Solanum lycopersicum/chemistry , Agriculture , Fertilizers/analysis , Fruit/chemistry , Humans , Metals, Heavy/analysis , Minerals , Soil , Transfer FactorABSTRACT
BACKGROUND: IMMUNEPOTENT CRP (ICRP) can be cytotoxic to cancer cell lines. However, its widespread use in cancer patients has been limited by the absence of conclusive data on the molecular mechanism of its action. Here, we evaluated the mechanism of cell death induced by ICRP in HeLa and MCF-7 cells. METHODS: Cell death, cell cycle, mitochondrial membrane potential and ROS production were evaluated in HeLa and MCF-7 cell lines after ICRP treatment. Caspase-dependence and ROS-dependence were evaluated using QVD.oph and NAC pre-treatment in cell death analysis. DAMPs release, ER stress (eIF2-α phosphorylation) and autophagosome formation were analyzed as well. Additionally, the role of autophagosomes in cell death induced by ICRP was evaluated using SP-1 pre-treatment in cell death in HeLa and MCF-7 cells. RESULTS: ICRP induces cell death, reaching CC50 at 1.25 U/mL and 1.5 U/mL in HeLa and MCF-7 cells, respectively. Loss of mitochondrial membrane potential, ROS production and cell cycle arrest were observed after ICRP CC50 treatment in both cell lines, inducing the same mechanism, a type of cell death independent of caspases, relying on ROS production. Additionally, ICRP-induced cell death involves features of immunogenic cell death such as P-eIF2α and CRT exposure, as well as, ATP and HMGB1 release. Furthermore, ICRP induces ROS-dependent autophagosome formation that acts as a pro-survival mechanism. CONCLUSIONS: ICRP induces a non-apoptotic cell death that requires an oxidative stress to take place, involving mitochondrial damage, ROS-dependent autophagosome formation, ER stress and DAMPs' release. These data indicate that ICRP could work together with classic apoptotic inductors to attack cancer cells from different mechanisms, and that ICRP-induced cell death might activate an immune response against cancer cells.
Subject(s)
Alarmins/metabolism , Antineoplastic Agents/pharmacology , Autophagosomes , Neoplasms/drug therapy , Reactive Oxygen Species/metabolism , Transfer Factor/administration & dosage , Animals , Apoptosis , Cattle , Cell Cycle , Cell Proliferation , HeLa Cells , Humans , MCF-7 Cells , Mitochondria/metabolism , Mitochondria/pathology , Neoplasms/pathology , Oxidative StressABSTRACT
Immunomodulatory agents have been proposed as therapeutic candidates to improve outcomes in sepsis. Transferon™, a dialyzable leukocyte extract (DLE), has been supported in Mexico as an immunomodulatory adjuvant in anti-infectious therapy. Here we present a retrospective study describing the experience of a referral pediatric intensive care unit (PICU) with Transferon™ in sepsis. We studied clinical and laboratory data from 123 patients with sepsis (15 in the DLE group and 108 in the control group) that were admitted to PICU during the period between January 2010 and December 2016. Transferon™ DLE use was associated with lower C reactive protein (CRP), increase in total lymphocyte counts (TLC), and decrease in total neutrophil count (TNC) 72 hours after Transferon™ DLE administration. The control group did not present any significant difference in CRP values and had lower TLC after 72 hours of admission. There was no difference in PICU length of stay between control and Transferon™ DLE group. Transferon™ DLE administration was associated with a higher survival rate at the end of PICU stay. This study shows a possible immunomodulatory effect of Transferon™ on pediatric sepsis patients.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Sepsis/drug therapy , Transfer Factor/therapeutic use , C-Reactive Protein/metabolism , Child , Female , Humans , Intensive Care Units, Pediatric , Lymphocyte Count , Male , Mexico , Neutrophils/drug effects , Neutrophils/metabolism , Retrospective Studies , Sepsis/metabolism , Sepsis/mortality , Survival RateABSTRACT
Transferon® is an immunomodulator made of a complex mixture of peptides from human dialyzable leucocyte extracts (hDLEs). Development of surrogate antibodies directed to hDLE is an indispensable tool for studies during process control and preclinical trials. These antibodies are fundamental for different analytical approaches, such as identity test and drug quantitation, as well as to characterize its pharmacokinetic and mechanisms of action. A previous murine study showed the inability of the peptides of Transferon® to induce antibody production by themselves; therefore, in this work, two approaches were tested to increase its immunogenicity: chemical conjugation of the peptides of Transferon® to carrier proteins and the use of a rabbit model. Bioconjugates were generated with Keyhole Limpet Hemocyanin (KLH) or Bovine Serum Albumin (BSA) through maleimide-activated carrier proteins. BALB/c mice and New Zealand rabbits were immunized with Transferon® conjugated to KLH or nonconjugated Transferon®. Animals that were immunized with conjugated Transferon® showed significant production of antibodies as evinced by the recognition of Transferon®-BSA conjugate in ELISA assays. Moreover, rabbits showed higher antibody titers when compared with mice. Neither mouse nor rabbits developed antibodies when immunized with nonconjugated Transferon®. Interestingly, rabbit antibodies were able to partially block IL-2 production in Jurkat cells after costimulation with Transferon®. In conclusion, it is feasible to elicit specific and functional antibodies anti-hDLE with different potential uses during the life cycle of the product.
Subject(s)
Isoantibodies/immunology , Transfer Factor/adverse effects , Adjuvants, Immunologic , Animals , Antibody Formation , Antibody Specificity/immunology , Antigens/administration & dosage , Antigens/immunology , Enzyme-Linked Immunosorbent Assay , Humans , Immunization , Immunoglobulin G/immunology , Immunoglobulin G/isolation & purification , Isoantibodies/isolation & purification , Male , Mice , Peptides/administration & dosage , Peptides/immunology , Rabbits , Transfer Factor/immunology , Transfer Factor/therapeutic useABSTRACT
Transferon® is a complex drug based on a mixture of low molecular weight peptides. This biotherapeutic is employed as a coadjuvant in clinical trials of several diseases, including viral infections and allergies. Given that macrophages play key roles in pathogen recognition, phagocytosis, processing, and antigen presentation, we evaluated the effect of Transferon® on phenotype and function of macrophage-like cells derived from THP-1 monocytes. We determined the surface expression of CD80 and CD86 by flow cytometry and IL-1ß, TNF-α, and IL-6 levels by ELISA. Transferon® alone did not alter the steady state of PMA-differentiated macrophage-like THP-1 cells. On the contrary, simultaneous stimulation of cells with Transferon® and LPS elicited a significant increase in CD80 (P ≤ 0.001) and CD86 (P ≤ 0.001) expression, as well as in IL-6 production (P ≤ 0.05) compared to the LPS control. CD80 expression and IL-6 production exhibited a positive correlation (r = 0.6, P ≤ 0.05) in cells exposed to Transferon® and LPS. Our results suggest that the administration of Transferon® induces the expression of costimulatory molecules and the secretion of cytokines in LPS-activated macrophages. Further studies are necessary to determine the implication of these findings in the therapeutic properties of Transferon®.
Subject(s)
B7-1 Antigen/genetics , Interleukin-6/immunology , Lipopolysaccharides/pharmacology , Macrophages/drug effects , Macrophages/immunology , Transfer Factor/pharmacology , B7-1 Antigen/immunology , B7-2 Antigen/genetics , B7-2 Antigen/immunology , Cell Differentiation/drug effects , Cytokines/immunology , Flow Cytometry , Humans , Leukocyte Count , Monocytes/drug effects , THP-1 CellsABSTRACT
BACKGROUND: Dialyzable leukocyte extracts (DLE) have been used to treat several cellular immunodeficiency. OBJECTIVE: To review the experience of a tertiary hospital in the use of DLE for the treatment of recurrent or severe infections in children with acquired cellular immunodeficiency not due to HIV. METHODS: We reviewed the medical records of all children who received treatment with EDL of human or bovine origin between 1986 and 2000 to detect recurrent or severe infections without response to a specific antimicrobial therapy and with a quantitative or qualitative deficit in the cellular immune response. The dose of DLE was adjusted according to the percentage of T lymphocytes; the evolution of the patient was evaluated retrospectively for 5 years, the immune response was evaluated by subpopulation of lymphocytes and intradermal tests and inhibition of the leukocyte migration assay (LIF) to PPD, coccidioidin, varidase and candidin. RESULTS: 150 children received DLE, age 7.0 ± 5.9 years. The most frequent indications included upper respiratory tract (71%), lower respiratory tract (43%), gastrointestinal tract (15%), urinary tract (15%) and neurological infections (4%) and coccidioidomycosis (3%). After starting the DLE, the numbers of T lymphocytes, LIF to PPD and varidase (> 20%) and the intradermal induration of the test increased (p <0.001). In 6 patients (4%) recurrences of respiratory and gastrointestinal tract infections were observed, which resolved, no adverse effects attributable to the DLE were reported. CONCLUSIONS: The use of DLE for recurrent or severe infectious processes in children with cellular immune deficit improved the clinical evolution and the immunological parameters evaluated without adverse effects attributable to their use.
Antecedentes: Los extractos dializados de leucocitos (EDL) han sido utilizados en el tratamiento de diversos defectos de la inmunidad celular. Objetivo: Revisar la experiencia en el uso de EDL para tratar infecciones recurrentes o severas en niños con inmunodeficiencia celular adquirida no debida a virus de la inmunodeficiencia oportuna. Métodos: Se revisaron expedientes de niños tratados con EDL humano o bovino entre 1986 y 2000, por infecciones recurrentes o severas sin respuesta a antimicrobianos y con déficit en la respuesta inmune celular. La dosis se ajustó por el porcentaje de poblaciones de linfocitos T. En el seguimiento a cinco años, la respuesta inmune se evaluó por subpoblaciones de linfocitos, intradermorreacción e inhibición de la migración de leucocitos (LIF) a PPD, coccidioidina, varidasa y candidina. Resultados: 150 niños recibieron EDL, edad 7.0 ± 5.9 años. Las indicaciones más frecuentes incluyeron infección respiratoria superior (71 %), respiratoria inferior (43 %), gastrointestinal (15 %), urinaria (15 %), neuroinfección (4 %) y coccidioidomicosis (3 %). Se incrementaron los linfocitos T, el LIF a PPD y varidasa (> 20 %), así como la induración en pruebas de intradermorreacción (p < 0.001). Se resolvieron las infecciones que se presentaron (4 %). No se reportaron efectos adversos. Conclusiones: El uso de EDL mejoró los parámetros inmunológicos y la evolución clínica en niños con déficit inmune celular.
Subject(s)
Immunologic Deficiency Syndromes/complications , Infections/immunology , Infections/therapy , Transfer Factor/therapeutic use , Child , Female , Humans , Male , Recurrence , Retrospective Studies , Severity of Illness Index , Time FactorsABSTRACT
BACKGROUND: Mycosis fungoides is a cutaneous T-cell lymphoma. The patch stage is limited to the skin and may spontaneously involute or progress, spreading to peripheral blood, lymph nodes and viscera. CASE REPORT: 64 year-old female with a 6-year history of dermatosis with scaly, poorly delimited and pruritic plaques on the chest and extremities. She had received oral steroids and antihistamines, with transient partial remissions been experienced. Skin biopsy revealed Pautrier's microabscesses, which are pathognomonic of mycosis fungoides. Positron-emission tomography and peripheral blood smear ruled out dissemination and confirmed patch-stage mycosis fungoides. She received nitrogen mustard topical derivatives, psoralen plus UVA therapy, steroids and tacrolimus. She achieved complete remission at 6 months. Two years later, she was treated with dialyzable leukocyte extract, which reactivated the patch lesions with severe itching; the extract was discontinued. The lesions resolved two weeks after topical clobetasol was applied. CONCLUSIONS: Th2 predominates in mycosis fungoides. Given that dialyzable leukocyte extract reinforces the Th1 profile, it was unlikely for it to reactivate the disease, but the diversity of lymphocyte immunophenotypes in mycosis fungoides and the complex activation networks caused a paradoxical reactivation.
Antecedentes: La micosis fungoide es un linfoma cutáneo de células T. El estadio de placa se encuentra limitado a piel y puede involucionar o progresar, diseminándose a sangre periférica, ganglios y vísceras. Reporte de caso: Mujer de 64 años de edad con dermatosis de seis años de evolución con placas descamativas, mal delimitadas y pruriginosas en tórax y extremidades. Había recibido esteroides orales y antihistamínicos, con los que presentaba remisiones parciales transitorias. Mediante biopsia cutánea se encontraron microabscesos de Pautrier, patognomónicos de micosis fungoide. La tomografía por emisión de positrones y el frotis de sangre periférica descartaron diseminación y confirmaron micosis fungoide en estadio de placa. La paciente recibió derivados tópicos de mostaza nitrogenada, psoralenos con radiaciones ultravioleta A, esteroides y tacrolimus. Presentó remisión total a los seis meses. Dos años después recibió extracto dializado de leucocitos, con el que se reactivaron las lesiones con prurito intenso; suspendió el extracto. Las lesiones involucionaron dos semanas después de iniciar el clobetasol tópico. Conclusiones: En la micosis fungoide predomina Th2. Dado que el extracto dializado de leucocitos refuerza el perfil Th1 no se esperaba que reactivara la enfermedad, pero los diversos inmunofenotipos de los linfocitos en la micosis fungoide y las complejas redes de activación ocasionaron reactivación paradójica.
Subject(s)
Mycosis Fungoides/chemically induced , Skin Neoplasms/chemically induced , Transfer Factor/administration & dosage , Administration, Oral , Female , Humans , Middle Aged , Mycosis Fungoides/pathology , Skin Neoplasms/pathologyABSTRACT
Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide. Dialyzed Leukocyte Extracts (DLEs) are heterogeneous mixtures of low-molecular-weight peptides that improve clinical responses in various diseases. Here, we analyzed the effects of TransferonTM, a commercial DLE with characterized active pharmaceutical ingredient and proven batch-to-batch reproducibility, in preclinical models of PCa. We employed v-Src-transformed murine prostate epithelial (PEC-Src) cells, which recapitulate the transcriptional profiles in human PCa, can be grown in immunocompetent mice, and consistently form bone and brain metastases. In vitro, TransferonTM did not induce cytotoxicity nor alterations in migration /invasion of PEC-Src cells. In vivo, TransferonTM reduced metastatic dissemination after intracardiac injection of PEC-Src and inhibited tumor growth of subcutaneous isotransplants. The antineoplastic effect of TransferonTM correlated with changes in tumor infiltration, increased serum concentrations of IL-12 and CXCL1, and reduced levels of VEGF. Our results suggest that the antineoplastic effect produced by TransferonTM is due to its immunomodulatory activity and not by a direct effect on cancer cells, and indicate that TransferonTM could be beneficial as adjuvant therapy in PCa patients.
Subject(s)
Brain Neoplasms/secondary , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/pathology , Transfer Factor/therapeutic use , Animals , Antineoplastic Agents/pharmacology , Cell Death/drug effects , Cell Line, Tumor , Cell Movement/drug effects , Cell Proliferation/drug effects , Cell Survival/drug effects , Disease Models, Animal , Interleukin-1/metabolism , Interleukin-12/metabolism , Male , Mice , Neoplasm Invasiveness , Transfer Factor/pharmacology , Vascular Endothelial Growth Factor A/metabolismABSTRACT
BACKGROUND: Dialyzable leukocyte extracts (DLEs) contain molecules smaller than 10 kDa with biological activity in receptor organisms. Primarily, they participate in the regulation of the Th1 immune response, which is essential for the control of several intracellular infections, such as toxoplasmosis. This disease is associated with congenital infection, encephalitis or systemic infections in immunocompromised individuals. The clinical course of this infection fundamentally depends on a well-regulated immune response and timely treatment with the appropriate drugs. OBJECTIVE: The aim of this study was to evaluate the effect of treatment with a leukocyte extract, derived from crocodile lymphoid tissue, on the histopathology and brain parasite load in NIH mice that had been infected with cysts of Toxoplasma gondii (ME-49 strain). METHODS: The treatment was applied during the acute and chronic stages of the infection. Histopathological changes were evaluated in the ileum, liver and spleen at one, four and eight weeks after infection and in the brain at week 8. The parasite load was evaluated by counting the cysts of T. gondii found in the brain. FINDINGS: Compared to the control mouse group, the mice infected with T. gondii and under treatment with DLE showed less tissue damage, mainly at the intestinal, splenic and hepatic levels. In addition, a greater percentage of survival was observed, and there was a considerable reduction in the parasite load in the brain. CONCLUSIONS: The results suggest that DLE derived from crocodile is a potential adjunctive therapy in the conventional treatment of toxoplasmosis.
Subject(s)
Brain/pathology , Spleen/pathology , Toxoplasmosis, Animal/drug therapy , Transfer Factor/therapeutic use , Alligators and Crocodiles , Animals , Brain/parasitology , Disease Models, Animal , Female , Lymphoid Tissue/chemistry , Mice , Parasite Load , Random Allocation , Spleen/parasitology , Toxoplasmosis, Animal/pathology , Transfer Factor/isolation & purificationABSTRACT
BACKGROUND Dialyzable leukocyte extracts (DLEs) contain molecules smaller than 10 kDa with biological activity in receptor organisms. Primarily, they participate in the regulation of the Th1 immune response, which is essential for the control of several intracellular infections, such as toxoplasmosis. This disease is associated with congenital infection, encephalitis or systemic infections in immunocompromised individuals. The clinical course of this infection fundamentally depends on a well-regulated immune response and timely treatment with the appropriate drugs. OBJECTIVE The aim of this study was to evaluate the effect of treatment with a leukocyte extract, derived from crocodile lymphoid tissue, on the histopathology and brain parasite load in NIH mice that had been infected with cysts of Toxoplasma gondii (ME-49 strain). METHODS The treatment was applied during the acute and chronic stages of the infection. Histopathological changes were evaluated in the ileum, liver and spleen at one, four and eight weeks after infection and in the brain at week 8. The parasite load was evaluated by counting the cysts of T. gondii found in the brain. FINDINGS Compared to the control mouse group, the mice infected with T. gondii and under treatment with DLE showed less tissue damage, mainly at the intestinal, splenic and hepatic levels. In addition, a greater percentage of survival was observed, and there was a considerable reduction in the parasite load in the brain. CONCLUSIONS The results suggest that DLE derived from crocodile is a potential adjunctive therapy in the conventional treatment of toxoplasmosis.
Subject(s)
Animals , Female , Mice , Brain/parasitology , Brain/pathology , Toxoplasmosis, Animal/pathology , Toxoplasmosis, Animal/drug therapy , Transfer Factor/isolation & purification , Transfer Factor/therapeutic use , Alligators and Crocodiles , Lymphoid Tissue/chemistry , Parasites , Spleen/parasitology , Disease Models, AnimalABSTRACT
OBJECTIVE: to evaluate the action of Transfer Factor on the immune response of patients with malignant neoplasm submitted to surgery, chemotherapy and radiotherapy. METHOD: we analyzed the variations of leukocytes, total lymphocytes, T-lymphocytes and CD4 counts in 60 patients submitted to immunostimulation with a single, daily dose of 0.5mg sublingual Transfer Factor, started simultaneously with chemotherapy and/or radiotherapy. RESULTS: there were statistically significant increases in the counts of all cell lines studied, more pronounced after 12 months of use of the medication. CONCLUSION: the Transfer Factor restored immune response and showed no side effects.
Subject(s)
Immunocompromised Host/drug effects , Neoplasms/immunology , Neoplasms/surgery , Transfer Factor/therapeutic use , Adult , Aged , Female , Humans , Male , Middle AgedABSTRACT
ABSTRACT Objective : to evaluate the action of Transfer Factor on the immune response of patients with malignant neoplasm submitted to surgery, chemotherapy and radiotherapy. Method: we analyzed the variations of leukocytes, total lymphocytes, T-lymphocytes and CD4 counts in 60 patients submitted to immunostimulation with a single, daily dose of 0.5mg sublingual Transfer Factor, started simultaneously with chemotherapy and/or radiotherapy. Results: there were statistically significant increases in the counts of all cell lines studied, more pronounced after 12 months of use of the medication. Conclusion: the Transfer Factor restored immune response and showed no side effects.
RESUMO Objetivo: avaliar a ação do Fator de Transferência na resposta imunológica de pacientes portadores de neoplasia maligna submetidos à cirurgia, quimioterapia e radioterapia. Método: análise das variações dos valores dos leucócitos, linfócitos totais, linfócitos T e CD4 em 60 pacientes submetidos à imunoestimulação com Fator de Transferência administrado em dose única de 0,5mg por via sublingual, diariamente e iniciada simultaneamente à quimioterapia e/ou radioterapia. Resultados: houve um aumento no número de todas as linhagens celulares estudadas que foi mais acentuada após 12 meses de uso da medicação. A análise estatística realizada com o software Graph Pad Instat, testadas pelo método Kolmogorov and Smirnov, mostrou que os resultados foram significativos. Conclusão: o Fator de Transferência restabeleceu a resposta imune e não apresentou efeitos colaterais.
Subject(s)
Humans , Male , Female , Adult , Aged , Transfer Factor/therapeutic use , Immunocompromised Host/drug effects , Neoplasms/surgery , Neoplasms/immunology , Middle AgedABSTRACT
Objective. To evaluate the anti-inflammatory properties of Dialyzable Leukocyte Extract (DLE) in a murine model of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Methods. Histopathological characterization, prostatein Enzyme-Linked Immunosorbent Assay, and immunohistochemical analysis for CD45, TNF-α, IFN-γ, IL-6, IL-17, and IL-4 molecules were done in prostatic Wistar rats treated with DLE, placebo, or Dexamethasone. Results. Histopathological analysis of animals induced to prostatitis showed inflammatory infiltrate, mainly constituted by leucocytes and mast cells as well as Benign Prostatic Hyperplasia. Serum prostatein concentrations were 14 times higher than those displayed by healthy animals. After DLE and Dexamethasone treatments, the inflammatory infiltrate decreased; the tissue morphology was similar to that of a normal prostate, and the prostatein decreased to the basal levels of healthy animals. DLE treatment produced a decreased expression of the cell surface marker CD45 and the proinflammatory cytokines TNF-α, IFN-γ, IL-6, and IL-17. On the other hand, the expression of anti-inflammatory cytokine IL-4 increased in both the Dexamethasone and DLE groups. Conclusion. DLE is able to modulate the inflammatory response in Experimental Autoimmune Prostatitis (EAP).
Subject(s)
Autoimmune Diseases/drug therapy , Inflammation/drug therapy , Prostatitis/drug therapy , Transfer Factor/administration & dosage , Animals , Autoimmune Diseases/blood , Autoimmune Diseases/pathology , Dexamethasone , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Gene Expression Regulation/drug effects , Humans , Inflammation/blood , Inflammation/pathology , Interleukin-17/biosynthesis , Interleukin-4/biosynthesis , Interleukin-6/biosynthesis , Leukocyte Common Antigens/biosynthesis , Male , Mice , Prostatein/blood , Prostatic Hyperplasia/blood , Prostatic Hyperplasia/drug therapy , Prostatic Hyperplasia/pathology , Prostatitis/blood , Prostatitis/pathology , Rats , Tumor Necrosis Factor-alpha/biosynthesisSubject(s)
Carbon Monoxide/blood , Exercise Tolerance , Smokers , Smoking/blood , Transfer Factor/blood , Adult , Exercise Test , Female , Humans , Male , Middle Aged , Smoking/physiopathology , SpirometryABSTRACT
The objective of the study was to assess the clinical, histopathological and immunochemical changes induced by dialyzable leukocyte extract (DLE) treatment in patients with chronic cervicitis associated to HPV infection. Fifty-four female Mexican patients diagnosed with chronic cervicitis, cervical intra-epithelial neoplasia grade 1 (CIN 1) and HPV infection were divided into two groups: patients treated with placebo and patients treated with DLE. Clinical and colposcopy evaluations were performed before and after treatments. Cervix biopsies were obtained to analyze histopathological features and to determine the local immunological changes by immunohistochemistry analyses. Placebo-treated patients showed no significant changes in the evaluated parameters. Interestingly, in DLE-treated patients, clinical manifestations of cervicitis diminished and 89% of them remitted the colposcopic lesions. Histological analyses of biopsies from DLE-treated patients showed a decreasing leukocyte infiltrate. Immunochemical analyses showed an increased expression of TGF-ß, while expression of IFN-γ, PCNA, and IL-32 decreased. Our results suggest that DLE can stimulate innate immunity of cervical mucosae, diminishing chronic cervicitis in HPV-infected patients. TRIAL REGISTRATION: Register ISRCTN16429164 Abbreviations: HPV = Human Papilloma Virus; DLE = Dialyzable leukocyte extract.
Subject(s)
Papillomavirus Infections/complications , Transfer Factor/therapeutic use , Uterine Cervicitis/complications , Uterine Cervicitis/drug therapy , Adult , Aged , Biopsy , Cervix Uteri/diagnostic imaging , Cervix Uteri/pathology , Chronic Disease , Colposcopy , Female , Humans , Immunohistochemistry , Interferon-gamma/metabolism , Interleukins/metabolism , Middle Aged , Papillomavirus Infections/virology , Proliferating Cell Nuclear Antigen/metabolism , Transforming Growth Factor beta/metabolism , Uterine Cervicitis/diagnostic imaging , Uterine Cervicitis/pathology , Young AdultABSTRACT
BACKGROUND: The transfer factor (TF) is the dialyzable extract of leukocytes with cellular immunity transfer properties. Its use has spread in the treatment of a wide range of immunologic, infectious, and even oncological diseases. However, important aspects in their protein profile, component concentrations, and a well-defined action mechanism are not completely unknown. OBJECTIVES: To analyze the protein profiles of different transfer factors marketed in Mexico. METHODS: 6 TF marketed in Mexico were obtained and analyzed, quantifying protein with thaze Bradford method, by high-performance liquid chromatography (HPLC), and polyacrylamide gel electrophoresis (SDS-PAGE). All samples were analyzed in duplicate. RESULTS: The total protein concentrations of all TF analyzed are less than 0.2 mg/mL. The chromatographic profiles showed differences in some TF. The protein concentration was 6 to almost one thousand times lower compared to reports by some manufacturers. CONCLUSION: Almost all transfer factors marketed in Mexico lack a labeling and health record that meets the official standards.
Introducción: El factor de transferencia (FT) es el extracto dializable de leucocitos con propiedades de transferencia de inmunidad celular. Su uso se ha extendido en el tratamiento de una amplia gama de padecimientos inmunológicos, infecciosos y como coadyuvante de padecimientos oncológicos. A pesar de ello, no se conocen completamente aspectos importantes de su perfil proteico, concentraciones de componentes y mecanismos de acción. Objetivos: Analizar los perfiles proteicos de diferentes factores de transferencia comercializados en México. Métodos: Se obtuvieron y analizaron 6 FT comercializados en México. Se realizó la cuantificación de proteínas por el método de Bradford, cromatografía líquida de alta resolución (HPLC) y electroforesis en geles de poliacrilamida (SDS-PAGE). Todas las muestras fueron analizadas por duplicado. Resultados: Las concentraciones de proteínas totales de todos los FT analizados fueron menores de 0.2 mg/mL. Los perfiles cromatográficos mostraron diferencias en algunos FT. La concentración de proteínas resultó de 6 hasta casi mil veces más baja en comparación con lo informado por algunos fabricantes. Conclusión: Casi la totalidad de los factores de transferencia comercializados en México carecen de un etiquetado y registro sanitario que cumpla con las normas oficiales vigentes.